Skip to main content

MCRB

Stock
Health Care
Biotechnology

Performance overview

MCRB Price
Price Chart

Forward-looking statistics

Beta
1.94
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.

Company info

SectorHealth Care
IndustryBiotechnology
Employees359
Market cap$93.0M

Fundamentals

Enterprise value$127.7M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity177.45

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$7.95
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth+1.0
Credit+7.2
Liquidity-0.2
Inflation-4.7
Commodities-2.8
Interest Rates-0.4

Valuation

Dividend yield0.00%
PEG Ratio-21.58
Price to sales
P/E Ratio-21.58
Enterprise Value to Revenue
Price to book2.05

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (May 23, 2025)
Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

Seres Therapeutics Inc (NASDAQ: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI).

Benzinga (June 7, 2022)
Will The Rally Continue In Seres Therapeutics (MCRB) Stock After A Stellar 77% Surge In A Month?

The stock price of Seres Therapeutics, a small late stage clinical biotechnology company with a market cap of around $1 billion, is up a whopping 77% in a month, while it is up 17% over the last week. There were multiple positive developments that supported the stock price growth for Seres.

Forbes (December 2, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free